Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
Vaccine|June 4, 2017
Rapid development of vaccines against emerging pathogens: The replication-deficient simian adenovirus platform technologySarah C Gilbert, George M Warimwe
Vaccines|July 2, 2021
What Constitutes Protective Immunity Following Yellow Fever Vaccination?Jolynne Mokaya, Derick Kimathi, Teresa Lambe, et al.
The Journal of General Virology|July 17, 2019
Rift Valley fever: biology and epidemiologyDaniel Wright, Jeroen Kortekaas, Thomas A Bowden, et al.
Molecular Immunology|March 2, 2015
Understanding Rift Valley fever: contributions of animal models to disease characterization and controlGema Lorenzo, Elena López-Gil, George M Warimwe, et al.
Methods in Molecular Biology (Clifton, N.J.)|October 14, 2015
Laboratory-Scale Production of Replication-Deficient Adenovirus Vectored VaccinesSusan J Morris, Alison V Turner, Nicola Green, et al.
Wellcome Open Research|January 28, 2020
Randomized, double-blinded, controlled non-inferiority trials evaluating the immunogenicity and safety of fractional doses of Yellow Fever vaccines in Kenya and UgandaDerick Kimathi, Aitana Juan, Philip Bejon, et al.
PLOS Global Public Health|March 24, 2023
The global burden of Chikungunya fever among children: A systematic literature review and meta-analysisDoris K Nyamwaya, Samuel M Thumbi, Philip Bejon, et al.
BMJ Public Health|August 4, 2025
Rift Valley fever seroprevalence and risk factors among human populations in Uganda's cattle corridor: a cross-sectional studyZacchaeus Anywaine, Daniel Wright, George M Warimwe, et al.
Nature Reviews. Immunology|June 18, 2021
Using cross-species vaccination approaches to counter emerging infectious diseasesGeorge M Warimwe, Michael J Francis, Thomas A Bowden, et al.
Plos Neglected Tropical Diseases|July 24, 2018
Systematic literature review of Rift Valley fever virus seroprevalence in livestock, wildlife and humans in Africa from 1968 to 2016Madeleine H A Clark, George M Warimwe, Antonello Di Nardo, et al.
Pageof 7